Thymalin is a calf-thymus polypeptide complex developed by Vladimir Khavinson and approved in Russia as an immunomodulator. The flagship claim, a 266-person elderly cohort reporting two- to four-fold mortality reductions over six years, comes from non-randomized Russian research, and a single-blind COVID-19 trial (n=80) reported halved hospital mortality in severe cases. No independent Western RCT exists, and the effect sizes are large enough that replication is the whole question.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Has Thymalin been tested in humans?
In Russia, yes. The key longevity study is a 6-8 year follow-up of 266 elderly people reporting 2.0-2.1-fold lower mortality on Thymalin and 4.1-fold on an annual combination with Epithalamin; a single-blind COVID-19 trial (n=80) reported halved hospital mortality. These are non-randomized or single-site Russian studies, not Western RCTs.
Is Thymalin an approved drug?
Approved in Russia (registration LS-000267) as a thymic immunomodulator. It is not FDA- or EMA-approved; outside Russia it circulates through compounding pharmacies and research suppliers with variable quality.
How does Thymalin work?
Its short peptides (KE, EW, EDP) are claimed to penetrate nuclei and bind DNA or histones, epigenetically regulating immune-system genes: stimulating T-cell maturation, activating hematopoietic stem-cell differentiation, and dampening IL-1, IL-6, IL-8 and TNF-alpha. The exact binding sequences remain uncharacterized.
What would change this rating?
Independent randomized trials outside Russia replicating the mortality and infection findings. The entry itself flags geographic bias, likely publication bias, and effect sizes dramatic enough to require replication before belief.
02Overview
Thymalin is a polypeptide complex isolated from calf thymus, developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is one of the most extensively studied thymic peptide bioregulators, with over 35 years of clinical research supporting its immunomodulatory and geroprotective properties.
Thymalin is a natural extract containing short peptides (KE, EW, EDP) that regulate gene expression through epigenetic mechanisms, restoring immune function and supporting cellular regeneration in aging organisms.
Key Characteristics: - Source: Calf thymus polypeptide complex - Active Components: Short peptides Lys-Glu (KE), Glu-Trp (EW), Glu-Asp-Pro (EDP) - Mechanism: Epigenetic gene regulation via DNA/histone binding - Primary Effects: Immunomodulation, stem cell activation, geroprotection - Clinical Status: Approved in Russia (registration LS-000267, 2010)
03Mechanisms of Action
Epigenetic Gene Regulation
Thymalin's short peptides (KE, EW, EDP) penetrate cell nuclei and nucleoli, binding complementarily to specific DNA sequences and/or histone proteins. This binding alters gene expression and synthesis of:
- Heat shock proteins (HSPs)
- Cytokines and immune system proteins
- Fibrinolysis system components
- Gerontogenes
- Proteins involved in differentiation, proliferation, and apoptosis of immune cells
The normalization of immune and antioxidant system proteins, regeneration processes, and hemostasis restores regulatory system functions and explains Thymalin's broad therapeutic efficacy.
Immune System Modulation
Thymalin normalizes differentiation, proliferation, and reduces apoptosis of lymphoid cells:
- Stimulates thymocyte differentiation into mature T-cells
- Activates CD28+ T-cell expansion — critical for viral immunity
- Modulates CD44 and CD117 expression on hematopoietic stem cells
- Increases NK-cell activity — natural killer cells for viral defense
- Reduces lymphopenia — common in severe infections and aging
Studies show Thymalin decreases CD44 expression on HSCs 2.8-fold and CD117 2.2-fold, indicating activation of stem cell differentiation pathways.
Anti-Inflammatory Effects
Thymalin prevents "cytokine storm" by reducing pro-inflammatory cytokines: - IL-1α (Interleukin-1 alpha) - IL-6 (Interleukin-6) - IL-8 (Interleukin-8) - TNF-α (Tumor necrosis factor alpha)
This mechanism is particularly relevant for severe viral infections like COVID-19, where cytokine storm is a primary cause of mortality.
Stem Cell Activation
Thymalin activates differentiation of human hematopoietic stem cells (HSCs):
- Increases CD28+ cells (mature T-cell marker) in blood
- Promotes HSC differentiation rather than quiescence
- Enhances tissue regeneration capacity
- Supports mesenchymal stem cell function
Cardiovascular Protection
Clinical studies demonstrate Thymalin improves cardiovascular parameters in elderly patients: - Reduced ischemic heart disease incidence - Lowered hypertension rates - Improved hemostasis and reduced hypercoagulability - Enhanced endothelial function
04Clinical Evidence
Longevity Studies (★★★ Strong)
Study: "Peptides of pineal gland and thymus prolong human life" — 6-8 year follow-up of 266 elderly persons
Findings: - Thymalin reduced mortality rate 2.0-2.1-fold versus control - Combined Thymalin + Epithalamin reduced mortality 2.5-fold - Annual 6-year Thymalin + Epithalamin protocol reduced mortality 4.1-fold
Health Improvements: - 2.0-2.4-fold decrease in acute respiratory disease incidence - Reduced manifestations of ischemic heart disease - Lower hypertension disease rates - Decreased osteoarthrosis and osteoporosis incidence - Normalized cardiovascular, endocrine, immune, and nervous systems
PMID: 14523363 — Khavinson VKh, Anisimov VN. Peptides of pineal gland and thymus prolong human life. Adv Gerontol. 2002;10(1):74-84.
COVID-19 Clinical Trial (★★ Moderate)
Study: Randomized single-blind controlled trial at Chita State Medical Academy, Russia (n=80)
Protocol: - Intervention: Thymalin 10mg/2mL IM daily × 10 days + standard therapy (n=36) - Control: Placebo (NaCl 0.9%) IM daily × 10 days + standard therapy (n=44) - Participants: Elderly patients with severe COVID-19 (CT-3 or CT-4, lung damage ≥50%)
Results: - Faster clinical improvement in Thymalin group - Higher rates of recovery from lymphopenia - Faster normalization of C-reactive protein, D-dimer, lymphocytes, and NK-cells - Halved hospital mortality in older patients with severe COVID-19
Mechanistic Findings: Thymalin action on HSC differentiation, including increased CD28+ cells, may be one mechanism activating immune response in COVID-19 patients. Severe COVID cases show decreased T-helper and cytotoxic lymphocyte numbers alongside reduced CD28 expression on their surface — Thymalin reverses this pattern.
DOI: 10.1134/S2079057021040068 — Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients. Adv Gerontol. 2021.
Infectious Disease Treatment (★★ Moderate)
Thymalin is effective against various infectious diseases:
- Hepatitis A and B — improved recovery rates
- Erysipelas — reduced inflammation and faster healing
- Meningococcal infection — enhanced immune response
- Typhoid fever — decreased severity and duration
- Pneumonia of various origins — improved outcomes
- Cavernous pulmonary tuberculosis — adjunct therapy benefits
Immune Restoration in Elderly (★★ Strong)
Long-term studies show Thymalin significantly improves immune parameters in aging:
- Increased T-lymphocyte counts
- Enhanced B-cell function
- Improved NK-cell activity
- Reduced age-related immunosenescence markers
- Decreased susceptibility to infections
05Uses
Uses
Based on Russian clinical studies:
Timing: - Best administered during seasonal transitions - Consider fall/winter for respiratory protection - Avoid during acute infections (wait until recovery)
06Safety Profile
Adverse Effects: Generally well-tolerated - Minimal reported side effects in clinical studies - No significant toxicity documented in 35+ years of use - Occasional mild injection site reactions
Contraindications: - Hypersensitivity to thymic preparations - Active autoimmune diseases (theoretical concern) - Pregnancy and lactation (insufficient data)
Drug Interactions: - May enhance effects of immunosuppressive drugs (caution) - Synergistic with Epitalon for geroprotection - Compatible with most standard therapies
07Comparison with Other Peptides
| Peptide | Source | Primary Action | Clinical Evidence |
|---|---|---|---|
| Thymalin | Calf thymus extract | Broad immunomodulation, geroprotection | ★★★ Strong (long-term studies) |
| Thymosin Alpha-1 | Synthetic | Specific T-cell activation | ★★ Moderate (cancer, viral infections) |
| Epitalon | Synthetic pineal peptide | Telomere activation, anti-aging | ★★ Moderate (animal > human) |
| Vilon | Synthetic thymic peptide | Local immunomodulation | ★ Limited |
Swipe table →
08Critical Analysis
Strengths
- Extensive Long-Term Data: 35+ years of clinical research with mortality data
- Broad Spectrum Activity: Works across multiple systems (immune, cardiovascular, nervous)
- Epigenetic Mechanism: Gene-level regulation, not just symptomatic
- Safety Profile: Well-tolerated with minimal side effects
- Natural Origin: Physiologic peptide complex rather than synthetic drug
Limitations
- Geographic Bias: Most research from Russian institutions
- Limited RCTs: Many studies observational or uncontrolled
- Mechanism Complexity: Exact DNA binding sequences not fully characterized
- Quality Variability: Natural extract subject to batch variation
- Regulatory Status: Not approved by FDA or EMA
Controversies
- Efficacy Claims: Some studies show dramatic effects (4.1x mortality reduction) that require replication
- Publication Bias: Russian gerontology literature may over-report positive findings
- Thymus Atrophy: Aging thymus shrinks — unclear if peptides restore tissue or just modulate remaining cells
- Cost/Benefit: Expensive for unproven longevity benefits in healthy individuals
09Future Research Directions
- DNA Sequencing Studies: Identify exact binding sites of KE, EW, EDP peptides
- Western RCTs: Independent replication in non-Russian populations
- Combination Therapies: Thymalin + modern senolytics or mTOR inhibitors
- Biomarker Development: Identify predictors of response
- Manufacturing Standardization: Synthetic vs. natural extract comparison
10Key Takeaways
- Thymalin is a thymic peptide bioregulator with 35+ years of clinical research supporting immunomodulatory and geroprotective effects
- Mechanism: Epigenetic gene regulation via short peptides (KE, EW, EDP) binding DNA/histones
- Strongest Evidence: Longevity studies showing 2-5x mortality reduction in elderly over 6 years
- Clinical Applications: Immune restoration, viral infections (including COVID-19), anti-aging protocol
- Safety: Well-tolerated with minimal side effects
- Limitations: Russian-only research, limited RCTs, regulatory status outside Russia
11Where to get it
Thymalin is sold mainly through gray-market vendors whose products are not independently tested. We don't link to sellers of compounds like this, affiliate or otherwise. How we make money
12Connections
13Sources
- Khavinson VKh, Anisimov VN. Peptides of pineal gland and thymus prolong human life. Adv Gerontol. 2002;10(1):74-84. PMID 14523363PubMed 14523363
- Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients. Adv Gerontol. 2021. DOI 10.1134/S2079057021040068DOI 10.1134/S2079057021040068
- Morozov VG, Khavinson VKh. Isolation, purification, and identification of an immunomodulatory polypeptide found in the thymus of calves and humans. Biokhimiya. 1981;46:1652-1659. PMID 7295826PubMed 7295826
- Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. DOI 10.1007/s10522-009-9249-8DOI 10.1007/s10522-009-9249-8
14Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.